Medicine and Dentistry
Patient
100%
Therapeutic Procedure
50%
Combination Therapy
35%
Inpatient
33%
Malignant Neoplasm
27%
Non Small Cell Lung Cancer
27%
Neoplasm
24%
Disease
21%
Oncology
19%
Overall Survival
17%
Clear Cell Renal Cell Carcinoma
16%
Lung Cancer
16%
Gastrointestinal Stromal Tumor
15%
Chemotherapy
14%
Survival
12%
Analysis
11%
Surgery
11%
Toxicity
9%
Biological Marker
9%
Immunotherapy
9%
Progression Free Survival
9%
Nivolumab
9%
Transitional Cell Carcinoma
8%
Cisplatin
8%
Radiation Therapy
8%
Systemic Therapy
8%
Clinical Trial
7%
Age
7%
Imatinib
7%
Diagnosis
7%
Soft Tissue Sarcoma
6%
Prostate Cancer
6%
Follow up
6%
Carboplatin
6%
Arm
6%
Cells
6%
Bladder Cancer
6%
Cancer
5%
Targeted Therapy
5%
Platinum
5%
Metastatic Carcinoma
5%
Nodular Melanoma
5%
Recurrent Disease
5%
Pembrolizumab
5%
Neoadjuvant Chemotherapy
5%
Adverse Event
5%
Muscle Invasive Bladder Cancer
5%
Phase II Trials
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
27%
Chemotherapy
23%
Neoplasm
15%
Diseases
15%
Malignant Neoplasm
14%
Overall Survival
13%
Cisplatin
12%
Toxicity
12%
Nivolumab
11%
Survival
10%
Progression Free Survival
9%
Immunotherapy
9%
Gastrointestinal Stromal Tumor
9%
Lung Cancer
9%
Renal Cell Carcinoma
8%
Carboplatin
8%
Platinum
7%
Gemcitabine
7%
Paclitaxel
7%
Imatinib
7%
Pembrolizumab
6%
Transitional Cell Carcinoma
6%
Solid Malignant Neoplasm
6%
Adverse Event
6%
Ipilimumab
5%
Drug
5%
Sunitinib
5%
Docetaxel
5%